These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23563855)

  • 1. 3T renal (23)Na-MRI: effects of desmopressin in patients with central diabetes insipidus.
    Haneder S; Michaely HJ; Konstandin S; Schad LR; Morelli JN; Krämer BK; Schoenberg SO; Lammert A
    MAGMA; 2014 Feb; 27(1):47-52. PubMed ID: 23563855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative in vivo 23Na MR imaging of the healthy human kidney: determination of physiological ranges at 3.0T with comparison to DWI and BOLD.
    Haneder S; Kettnaker P; Konstandin S; Morelli JN; Schad LR; Schoenberg SO; Michaely HJ
    MAGMA; 2013 Dec; 26(6):501-9. PubMed ID: 23475308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of incidence of hyponatremia between intranasal and oral desmopressin in patients with central diabetes insipidus.
    Kataoka Y; Nishida S; Hirakawa A; Oiso Y; Arima H
    Endocr J; 2015; 62(2):195-200. PubMed ID: 25382102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral administration of diluted nasal desmopressin in managing neonatal central diabetes insipidus.
    Mavinkurve M; McGrath N; Johnston N; Moloney S; Murphy NP; Hawkes CP
    J Pediatr Endocrinol Metab; 2017 May; 30(6):623-628. PubMed ID: 28599389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of central diabetes insipidus using oral DDAVP. Comparison with intranasal treatment].
    Carraro A; Fano M; Porcella E; Bernareggi V; Giusti M
    Minerva Endocrinol; 1991; 16(3):141-5. PubMed ID: 1806811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buccally Administered Intranasal Desmopressin Acetate for the Treatment of Neurogenic Diabetes Insipidus in Infancy.
    Smego AR; Backeljauw P; Gutmark-Little I
    J Clin Endocrinol Metab; 2016 May; 101(5):2084-8. PubMed ID: 27011115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a new antidiuretic agent, desmopressin acetate (DDAVP).
    Kosman ME
    JAMA; 1978 Oct; 240(17):1896-7. PubMed ID: 691204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical evaluation of desmopressin (DDAVP) in diabetes insipidus: solution vs tablets].
    Rampazzo AL; Boscaro M; Mantero F; Piccitto R
    Minerva Endocrinol; 1992; 17(1):37-41. PubMed ID: 1495453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of cranial diabetes insipidus with oral desmopressin (DDAVP).
    Cunnah D; Ross G; Besser GM
    Clin Endocrinol (Oxf); 1986 Mar; 24(3):253-7. PubMed ID: 3708875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations.
    Kim RJ; Malattia C; Allen M; Moshang T; Maghnie M
    Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():115-23. PubMed ID: 16456490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe hyponatremia due to desmopressin.
    Kelleher HB; Henderson SO
    J Emerg Med; 2006 Jan; 30(1):45-7. PubMed ID: 16434334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of subcutaneous DDAVP in infants with central diabetes insipidus.
    Blanco EJ; Lane AH; Aijaz N; Blumberg D; Wilson TA
    J Pediatr Endocrinol Metab; 2006 Jul; 19(7):919-25. PubMed ID: 16995572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-term treatment of central diabetes insipidus with oral DDAVP].
    Carraro A; Fano M; Cuttica M; Bernareggi V; Giusti M; Giordano G
    Minerva Endocrinol; 1992; 17(4):189-93. PubMed ID: 1308923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, pharmacodynamics, long-term efficacy and safety of oral 1-deamino-8-D-arginine vasopressin in adult patients with central diabetes insipidus.
    Lam KS; Wat MS; Choi KL; Ip TP; Pang RW; Kumana CR
    Br J Clin Pharmacol; 1996 Sep; 42(3):379-85. PubMed ID: 8877030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The treatment of patients with diabetes insipidus by a synthetic analogue of vasopressin, DDAVP (author's transl)].
    Tanae A; Shimizu K; Yoshida S
    Nihon Naibunpi Gakkai Zasshi; 1978 May; 54(5):676-91. PubMed ID: 689212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DDAVP in the treatment of central diabetes insipidus.
    Robinson AG
    N Engl J Med; 1976 Mar; 294(10):507-11. PubMed ID: 1250255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the antidiuretic effects of single intravenous and intranasal doses of DDAVP in diabetes insipidus.
    Radó JP; Marosi J; Fischer J
    Pharmacology; 1977; 15(1):40-5. PubMed ID: 840889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desmopressin orally disintegrating tablet in Japanese patients with central diabetes insipidus: a retrospective study of switching from intranasal desmopressin.
    Murakami T; Hatoko T; Nambu T; Matsuda Y; Matsuo K; Yonemitsu S; Muro S; Oki S
    Endocr J; 2014; 61(8):773-9. PubMed ID: 24849384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of diabetes insipidus with Minirin. Switch from nasal to oral administration].
    Czernichow P
    Ann Endocrinol (Paris); 1998 Dec; 59(5):407-9. PubMed ID: 9949892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DDAVP (1-desamino-8-D-arginine-vasopressin) treatment of central diabetes insipidus--mechanism of prolonged antidiuresis.
    Seif SM; Zenser TV; Ciarochi FF; Davis BB; Robinson AG
    J Clin Endocrinol Metab; 1978 Mar; 46(3):381-8. PubMed ID: 221517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.